Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Castells, M ^a,b   Milhas, D ^a,b   Gandy, C ^a,b   Thibault, B ^a,b   Rafii, A ^a,b   Delord, J P ^a,b   Couderc, B ^a,b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Chemoresistance; Mesenchymal stem cells; Microenvironment; Ovarian cancer; XIAP

Indexed keywords

CARBOPLATIN; CASPASE 3; CASPASE 7; EFFECTOR CASPASE; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROPIDIUM IODIDE; PROTEIN KINASE B; SMALL INTERFERING RNA; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; MESENCHYME CELL; MICROENVIRONMENT; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; CARBOPLATIN; CASPASE 3; CASPASE 7; CELL LINE; CELL LINE, TUMOR; CISPLATIN; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MESENCHYMAL STROMAL CELLS; OVARIAN NEOPLASMS; TRANSFECTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84887444286     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.384     Document Type: Article

References (51)

1. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer 2011; 11: 719-725
2. Agarwal R, Kaye SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-516
3. Basak GW, Srivastava AS, Malhotra R, Carrier E. Multiple myeloma bone marrow niche. Curr. Pharm. Biotechnol. 2009; 10: 345-346
4. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat Rev Cancer 2009; 9: 665-674
5. Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR et al. Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem. 2007; 101: 135-146
6. Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 2011; 20: 370-383
7. Castells M, Thibault B, Mery E, Golzio M, Pasquet M, Hennebelle I et al. Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages. Cancer Lett. 2012; 32: 59-68
8. Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P et al. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat. 2010; 121: 293-300
9. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-563
10. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4: E4992
11. Alt E, Yan Y, Gehmert S, Song YH, Altman A, Gehmert S et al. Fibroblasts share mesenchymal phenotypes with stem cells, but lack their differentiation and colony-forming potential. Biol Cell 2011; 103: 197-208
12. Xu Y, Tabe Y, Jin L, Watt J, McQueen T, Ohsaka A et al. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol 2008; 142: 192-201
13. Hao M, Zhang L, An G, Meng H, Han Y, Xie Z et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma 2011; 52: 1787-1794
14. Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008; 7: 48-58
15. Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P et al. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 2010; 126: 2090-2101
16. Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 2011; 278: 3226-3245
17. Rafii A, Mirshahi P, Poupot M, Faussat AM, Simon A, Ducros E et al. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS One 2008; 3: E3894
18. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: Development of a reliable and reproducible system to assess stromal cell adhesionmediated drug resistance. Blood 2009; 114: 4441-4450
19. Castells M, Thibault B, Delord JP, Couderc B. Implication of tumor microenvironment in chemoresistance: Tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci 2012; 13: 9545-9571
20. OGorman DM, Cotter TG. Molecular signals in anti-apoptotic survival pathways. Leukemia 2001; 15: 21-34
21. Chipuk JE, Green DR. Do inducers of apoptosis trigger caspase-independent cell death? Nat Rev Mol Cell Biol 2005; 6: 268-275
22. Ding Z, Yang X, Pater A, Tang SC. Resistance to apoptosis is correlated with the reduced caspase-3 activation and enhanced expression of antiapoptotic proteins in human cervical multidrug-resistant cells. Biochem Biophys Res Commun 2000; 270: 415-420
23. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: The role of apoptotic regulators. Reprod Biol Endocrinol 2003; 1: 66
24. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 2003; 63: 7081-7088
25. Schneiderman D, Kim JM, Senterman M, Tsang BK. Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells. Apoptosis 1999; 4: 271-281
26. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001; 61: 1862-1868
27. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, LiM et al. Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins. Endocrinology 2001; 142: 370-380
28. Srinivasula SM, Ashwell JD. IAPs: Whats in a name? Mol Cell 2008; 30: 123-135
29. Fanning J, Biddle WC, Goldrosen M, Crickard K, Crickard U, Piver MS et al. Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay. Gynecol Oncol 1990; 39: 119-122
30. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-1883
31. Wu GS, Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 2002; 21: 1-8
32. Gyrd-Hansen M, Meier P. IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574
33. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 5405-5412
34. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-304
35. Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M et al. Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells 2008; 26: 789-797
36. Dent P, Grant S, Fisher PB, Curiel DT. PI3K: A rational target for ovarian cancer therapy? Cancer Biol Ther 2009; 8: 27-30
37. Kuehn HS, Jung MY, Beaven MA, Metcalfe DD, Gilfillan AM. Prostaglandin E2 activates and utilizes mTORC2 as a central signalling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem 2011; 286: 391-402
38. Leone V, di PA, Ricchi P, Acquaviva F, Giannouli M, Di Prisco AM et al. PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation. Am J Physiol Gastrointest Liver Physiol 2007; 293: G673-G681
39. Grey A, Chen Q, Callon K, Xu X, Reid IR, Cornish J. The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signalling pathway involving G(i) proteins and phosphatidylinositol-3 kinase. Endocrinology 2002; 143: 4755-4763
40. Morales-Ruiz M, Lee MJ, Zollner S, Gratton JP, Scotland R, Shiojima I et al. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem 2001; 276: 19672-19677
41. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010; 295: 110-123
42. Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011; 56: 365-375
43. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006; 13: 179-188
44. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 2011; 54: 2714-2726
45. Brunckhorst MK, Lerner D, Wang S, Yu Q. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther 2012; 13: 804-811
46. Rafii A, Mirshahi P, Poupot M, Faussat AM, Simon A, Ducros E et al. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS One 2008; 3: E3894
47. Lis R, Capdet J, Mirshahi P, Lacroix-Triki M, Dagonnet F, Klein C et al. Oncologic trogocytosis with Hospicells induces the expression of N-cadherin by breast cancer cells. Int J Oncol 2010; 37: 1453-1461
48. Mirshahi M, Mirshahi S, Golestaneh N, Nicolas C, Mishal Z, Lounes KC et al. Mineralocorticoid hormone signalling regulates the epithelial sodium channel in fibroblasts from human cornea. Ophthalmic Res 2001; 33: 7-19
49. Benard J, Da SJ, De Blois MC, Boyer P, Duvillard P, Chiric E et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985; 45: 4970-4979
50. Le MK, Lincet H, Marcelo P, Lemoisson E, Heutte N, Duval M et al. A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment. Proteomics 2007; 7: 4090-4101
51. Martinet L, Poupot R, Mirshahi P, Rafii A, Fournie JJ, Mirshahi M et al. Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. Int J Cancer 2010; 126: 2143-2152